Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population

Liu, J.M.; Liu, J.N.; Wei, Min; Ya, HE; Zhou, Yi; Song, Xingbo; Ying, Binwu; Huang, Jianlin

doi:10.4238/2013.march.15.2

Cited by 26 publications

(26 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a trend of reduced cancer risk was found in genitourinary system cancer, including prostate cancer [12], [40], renal cell carcinoma [33] and bladder cancer [39]. These results suggested that the variant CA and CA/AA genotypes of IL-18 gene promoter −607 C>A polymorphism were definitive associated with cancer susceptibility, especially in nasopharyngeal carcinoma and gastrointestinal cancer.…”

Section: Discussionmentioning

confidence: 92%

“…In the study reported by Haghshenas and colleagues, the cancer types contained colorectal and stomach cancer, and the genotype frequencies were presented separately, thus each of them was considered as a separate study in this meta-analysis. A total of 23 studies for −607 C>A and 21 studies for −137G>C were finally included with 4096 cases and 5222 controls according to selection criteria[10]–[16], [23]–[40]. The detailed characteristics of the eligible studies included in this meta-analysis are shown in Table 1.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association of Interleukin-18 Gene Promoter −607 C>A and −137G>C Polymorphisms with Cancer Risk: A Meta-Analysis of 26 Studies

Yang

Qiu²,

Hu³

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundEvidence suggest that IL-18 gene polymorphisms may be risk factors for several cancers. Increasing studies investigating the association between IL-18 gene promoter polymorphisms (−607 C>A and −137G>C) and cancer risk have yielded conflicting results.Methodology/Principal FindingsWe performed a meta-analysis of 26 studies including 4096 cases and 5222 controls. We assessed the strength of the association of IL-18 gene promoter −607 C>A and −137G>C polymorphisms with cancer risk and performed sub-group analyses by cancer types, ethnicities, source of controls and sample size. The pooled results revealed a significant increased risk of cancer susceptibility for −607 C>A (CA vs. CC: OR = 1.19, 95%CI: 1.04, 1.37, Pheterogeneity = 0.033; CA/AA vs. CC: OR = 1.17, 95% CI: 1.01, 1.34, Pheterogeneity = 0.007), but no significant association for −137 G>C was observed with overall cancer risk. Sub-group analyses revealed that an increased risk of nasopharyngeal carcinoma was both found for −607 C>A (CA/AA vs. CC: OR = 1.32, 95% CI: 1.04, 1.69, Pheterogeneity = 0.823) and −137G>C (GC/CC vs. GG: OR = 1.57, 95%CI: 1.26, 1.96, Pheterogeneity = 0.373). Consistent with the results of the genotyping analyses, the −607A/−137C and −607C/−137C haplotypes were associated with a significantly increased risk of nasopharyngeal carcinoma as compared with the −607C/−137G haplotype (−607A/−137C vs. −607C/−137G: OR = 1.26, 95%CI: 1.13, 1.40; Pheterogeneity = 0.569; −607C/−137C vs. −607C/−137G: OR = 1.14, 95%CI: 1.03, 1.27; Pheterogeneity = 0.775). As for gastrointestinal cancer, we also found that −607 C>A polymorphism was significantly associated with increased cancer risk (CA/AA vs. CC: OR = 1.25, 95% CI: 1.05, 1.50, Pheterogeneity = 0.458). Further sub-group analysis revealed that −137G>C polymorphism contributed to cancer risk in Asians but not in Caucasians (GC/CC vs. GG: OR = 1.31, 95%CI: 1.05, 1.64, Pheterogeneity<0.001).ConclusionsThe meta-analysis results suggest that IL-18 gene promoter −607 C>A polymorphism is significantly associated with overall cancer risk, especially in nasopharyngeal carcinoma and gastrointestinal cancer; and the −137 G>C polymorphism is associated with increased overall cancer risk in Asian populations and also significantly increases the risk of nasopharyngeal carcinoma.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Association of Interleukin-18 Gene Promoter −607 C>A and −137G>C Polymorphisms with Cancer Risk: A Meta-Analysis of 26 Studies

Yang

Qiu²,

Hu³

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that IL-18 sequence variations are associated with several diseases, including tuberculosis, rheumatoid arthritis, Crohn's disease, Helicobacter pylori infection, ischemic stroke, hepatitis B virus (HBV)-related liver disease, hepatocellular carcinoma, and other cancers (Liu et al, 2013;Angelo et al, 2015;Bao et al, 2015a;Gao et al, 2015;Karra et al, 2015;Li et al, 2015b;Myung et al, 2015;Shi et al, 2015;Zhou et al, 2015). Zhou et al (2015) examined the association between the polymorphisms under investigation in the present study and tuberculosis, reporting that the -137G/C variant contributes to susceptibility to this disease in the Han Chinese population.…”

Section: Discussionmentioning

confidence: 99%

Influence of interleukin-18 gene polymorphisms on acute pancreatitis susceptibility in a Chinese population

Gui

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We investigate the relationship between IL-18 -607C/ A and -137G/C genetic polymorphisms and development of acute pancreatitis in a Chinese population. A total of 153 patients were consecutively recruited from the First Affiliated Hospital of Chongqing Medical University between January 2013 and November 2014. Genotyping of IL-18 -607C/A and -137G/C variants was performed using the polymerase chain reaction-restriction fragment length polymorphism method. We observed a significant difference between acute pancreatitis patients and control subjects with respect to age (t = 2.15, P = 0.02), gender (chi-square = 3.95, P = 0.04), body mass index (t = 5.85, P < 0.001), and alcohol consumption (chi-square = 9.74, P = 0.002). Using chi-square tests, we found that the genotype distributions of IL-18 -607C/A (chi-square = 0.81, P = 0.67) and -137G/C (chisquare = 1.16, P = 0.56) polymorphisms did not differ between the acute pancreatitis and control groups. Genotype frequencies of these variants were consistent with Hardy-Weinberg equilibrium in both patient and control groups. In addition, logistic regression analysis failed to identify a significant association between these polymorphisms and acute pancreatitis risk. Our study firstly examined their association in a Chinese population, and we suggest that the IL-18 -607C/A and -137G/ C polymorphisms do not influence susceptibility to acute pancreatitis in the Chinese population studied in the present study.

show abstract

“…Surprisingly, genetic variation in the androgen receptor has not been linked to ADT response although other hormone signaling factors appear to be related. Other candidate gene studies have focused on the vitamin D receptor [163], RNASEL [164] and IL18 [165] with mixed results.…”

Section: Pharmacogenetics Of Drugs Used To Treat Prostate Cancermentioning

confidence: 99%

“…Findings include polymorphisms in genes encoding: BNC2, TACC2, ALPK1, KIF3C, CDON, IFI30, PALLD, GABRA1, SYT9, MSMB, MYCN, PSMD7, CCL17, MON1B, CASP3, BMP5, IRS2, TRMT11, PRMT3, and HSD17B2 [165–172]. Results from these studies suggest that the most important predictors of a poor response to ADT are not necessarily within androgen-related genes; however, the genetic variants identified in these studies have not been sufficiently validated from a mechanistic standpoint.…”

Section: Pharmacogenetics Of Drugs Used To Treat Prostate Cancermentioning

confidence: 99%

Genetic variation: effect on prostate cancer

Sissung

Price

et al. 2014

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Summary The crucial role of androgens in the development of prostate cancer is well established. The aim of this review is to examine the role of constitutional (germline) and tumor-specific (somatic) polymorphisms within important regulatory genes of prostate cancer. These include genes encoding enzymes of the androgen biosynthetic pathway, the androgen receptor gene, genes that encode proteins of the signal transduction pathways that may have a role in disease progression and survival, and genes involved in prostate cancer angiogenesis. Characterization of deregulated pathways critical to cancer cell growth have lead to the development of new treatments, including the CYP17 inhibitor abiraterone and clinical trials using novel drugs that are ongoing or recently completed [1]. The pharmacogenetics of the drugs used to treat prostate cancer will also be addressed. This review will define how germline polymorphisms are known affect a multitude of pathways, and therefore phenotypes, in prostate cancer etiology, progression, and treatment.

show abstract

Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population

Cited by 26 publications

References 38 publications

Association of Interleukin-18 Gene Promoter −607 C>A and −137G>C Polymorphisms with Cancer Risk: A Meta-Analysis of 26 Studies

Association of Interleukin-18 Gene Promoter −607 C>A and −137G>C Polymorphisms with Cancer Risk: A Meta-Analysis of 26 Studies

Influence of interleukin-18 gene polymorphisms on acute pancreatitis susceptibility in a Chinese population

Genetic variation: effect on prostate cancer

Contact Info

Product

Resources

About